Q4 EPS Estimate for Sagimet Biosciences Decreased by Analyst

Key Points

• HC Wainwright lowered Sagimet’s Q4 2026 EPS estimate to a loss of $0.32 per share from $0.30, while the full-year consensus estimate stands at a loss of $1.15 per share.
• Sagimet reported quarterly EPS of $(0.26), missing analysts’ $(0.25) estimate by $0.01. Shares opened at $9.39, near the company’s 52-week high of $10.06.
• Analyst sentiment remains generally positive, with seven Buy ratings, two Holds and one Sell, producing a “Moderate Buy” consensus and an average price target of $26.33; however, insiders sold 113,646 shares worth about $920,491 over the past 90 days.

Sagimet Biosciences Inc. (NASDAQ:SGMT - Free Report) - Equities researchers at HC Wainwright cut their Q4 2026 earnings per share estimates for Sagimet Biosciences in a report issued on Tuesday, August 11th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.32) per share for the quarter, down from their prior estimate of ($0.30). The consensus estimate for Sagimet Biosciences' current full-year earnings is ($1.15) per share.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group boosted their price objective on shares of Sagimet Biosciences from $49.00 to $56.00 and gave the stock a "buy" rating in a report on Wednesday. Citizens Jmp lowered their price objective on shares of Sagimet Biosciences from $35.00 to $12.00 and set a "market outperform" rating for the company in a research note on Tuesday, May 19th. Guggenheim decreased their price objective on shares of Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Wednesday, April 29th. Oppenheimer reiterated an "outperform" rating on shares of Sagimet Biosciences in a research note on Friday, May 1st. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Sagimet Biosciences in a report on Friday, July 17th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Sagimet Biosciences has a consensus rating of "Moderate Buy" and an average price target of $26.33.

Sagimet Biosciences Stock Down 1.4%

Shares of NASDAQ:SGMT opened at $9.39 on Thursday. The company has a 50-day moving average price of $7.39 and a 200 day moving average price of $6.52. The company has a market cap of $305.93 million, a P/E ratio of -7.34 and a beta of 3.37. Sagimet Biosciences has a 52 week low of $4.50 and a 52 week high of $10.06.

Sagimet Biosciences (NASDAQ:SGMT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.01).

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC boosted its holdings in shares of Sagimet Biosciences by 82.6% in the first quarter. Renaissance Technologies LLC now owns 625,469 shares of the company's stock valued at $3,268,000 after acquiring an additional 282,969 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Sagimet Biosciences by 99.4% during the first quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company's stock worth $1,415,000 after purchasing an additional 135,178 shares during the period. Dumac Inc. purchased a new stake in Sagimet Biosciences during the fourth quarter valued at about $421,000. China Universal Asset Management Co. Ltd. acquired a new position in Sagimet Biosciences in the 4th quarter worth approximately $30,000. Finally, Royal Bank of Canada grew its holdings in shares of Sagimet Biosciences by 819.2% during the fourth quarter. Royal Bank of Canada now owns 4,927 shares of the company's stock valued at $29,000 after buying an additional 4,391 shares in the last quarter. Institutional investors own 87.86% of the company's stock.

Insider Buying and Selling at Sagimet Biosciences

In other Sagimet Biosciences news, Director George Kemble sold 20,206 shares of Sagimet Biosciences stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total value of $201,049.70. Following the completion of the transaction, the director directly owned 62,161 shares in the company, valued at $618,501.95. The trade was a 24.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Elizabeth Rozek sold 10,545 shares of the business's stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $7.76, for a total value of $81,829.20. Following the transaction, the insider owned 224,414 shares of the company's stock, valued at $1,741,452.64. This represents a 4.49% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 113,646 shares of company stock worth $920,491 over the last ninety days. Company insiders own 11.50% of the company's stock.

More Sagimet Biosciences News

Here are the key news stories impacting Sagimet Biosciences this week:

• Positive Sentiment: Canaccord raises price target: Canaccord Genuity lifted its target for Sagimet from $49 to $56 and maintained a “buy” rating, implying substantial potential upside from recent trading levels. The upgrade reflects a bullish view of the company’s development prospects. Benzinga analyst price target report
• Positive Sentiment: Progress on denifanstat: Wedbush Securities said Sagimet is making “good progress” toward bringing denifanstat to U.S. patients. Positive commentary on the company’s lead drug candidate could support sentiment because future valuation depends heavily on clinical and regulatory execution. Sagimet making progress on denifanstat
• Neutral Sentiment: Short-interest data appears unreliable: Reported short interest was zero shares, unchanged from the prior period, with a zero days-to-cover ratio. Because the figures include an undefined percentage change and may reflect incomplete reporting, they provide little meaningful insight into trading pressure.
• Negative Sentiment: Quarterly loss slightly exceeded expectations: Sagimet reported a second-quarter 2026 loss of $0.26 per share, compared with analysts’ expectation of a $0.25 loss. The modest earnings miss reinforces that the company remains loss-making while it advances its pipeline. Sagimet second-quarter 2026 results
• Negative Sentiment: Director reduced holdings: Director George Kemble sold 20,206 shares for approximately $201,050, reducing his direct ownership by 24.5%. While insider sales can be routine, the transaction may weigh on sentiment because it signals reduced personal exposure by a company director.

Sagimet Biosciences Company Profile

Sagimet Biosciences NASDAQ: SGMT is a clinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases. The company's lead program, CM-101, is a first-in-class fusion protein designed to neutralize the chemokine CCL24 and interrupt key drivers of tissue fibrosis. Preclinical data have demonstrated CM-101's potential to block fibrotic signaling pathways in multiple organ systems, and the company has advanced the program into early-stage clinical evaluation for indications such as nonalcoholic steatohepatitis and systemic sclerosis.

In addition to CM-101, Sagimet maintains a pipeline of preclinical candidates targeting inflammation-driven fibrotic processes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source